One-on-One: TDD Talks to Brian Hilberdink, LEO Pharma’s EVP of North America, About Congenital Ichthyosis
LEO Pharma recently acquired TMB-001 and other assets from Timber Pharmaceuticals following Timber’s Chapter 11 bankruptcy filing. TMB-001 is an investigational topical reformulation of isotretinoin that is being studied in congenital ichthyosis (CI). The reformulation has received orphan, fast track, and breakthrough designation by the FDA. TMB-001 has shown positive results in Phase 2, with […]